Literature DB >> 20190796

Targeted therapies: Thalidomide in lung cancer therapy-what have we learned?

Martin Reck, Ulrich Gatzemeier.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20190796     DOI： 10.1038/nrclinonc.2010.11

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  9 in total

1.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

Authors:  Alan Sandler; Robert Gray; Michael C Perry; Julie Brahmer; Joan H Schiller; Afshin Dowlati; Rogerio Lilenbaum; David H Johnson
Journal:  N Engl J Med       Date:  2006-12-14       Impact factor: 91.245

2.  Randomized double-blind placebo-controlled trial of thalidomide in combination with gemcitabine and Carboplatin in advanced non-small-cell lung cancer.

Authors:  Siow Ming Lee; Robin Rudd; Penella J Woll; Christian Ottensmeier; David Gilligan; Allan Price; Stephen Spiro; Nicole Gower; Mark Jitlal; Allan Hackshaw
Journal:  J Clin Oncol       Date:  2009-09-21       Impact factor: 44.544

3.  Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial.

Authors:  Siow Ming Lee; Penella J Woll; Robin Rudd; David Ferry; Mary O'Brien; Gary Middleton; Stephen Spiro; Lindsay James; Kulsam Ali; Mark Jitlal; Allan Hackshaw
Journal:  J Natl Cancer Inst       Date:  2009-07-16       Impact factor: 13.506

4.  Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.

Authors:  Martin Reck; Joachim von Pawel; Petr Zatloukal; Rodryg Ramlau; Vera Gorbounova; Vera Hirsh; Natasha Leighl; Jörg Mezger; Venice Archer; Nicola Moore; Christian Manegold
Journal:  J Clin Oncol       Date:  2009-02-02       Impact factor: 44.544

5.  Phase II trial of thalidomide with chemotherapy and as maintenance therapy for patients with poor prognosis small-cell lung cancer.

Authors:  Siow Ming Lee; Lindsay James; Tomas Buchler; Mike Snee; Paul Ellis; Allan Hackshaw
Journal:  Lung Cancer       Date:  2007-10-24       Impact factor: 5.705

Review 6.  Thalidomide.

Authors:  Michael E Franks; Gordon R Macpherson; William D Figg
Journal:  Lancet       Date:  2004-05-29       Impact factor: 79.321

7.  Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab--an Eastern Cooperative Oncology Group Study.

Authors:  Afshin Dowlati; Robert Gray; Alan B Sandler; Joan H Schiller; David H Johnson
Journal:  Clin Cancer Res       Date:  2008-03-01       Impact factor: 12.531

8.  Thalidomide is an inhibitor of angiogenesis.

Authors:  R J D'Amato; M S Loughnan; E Flynn; J Folkman
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

9.  Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents.

Authors:  Yuval Shaked; Erik Henke; Jeanine M L Roodhart; Patrizia Mancuso; Marlies H G Langenberg; Marco Colleoni; Laura G Daenen; Shan Man; Ping Xu; Urban Emmenegger; Terence Tang; Zhenping Zhu; Larry Witte; Robert M Strieter; Francesco Bertolini; Emile E Voest; Robert Benezra; Robert S Kerbel
Journal:  Cancer Cell       Date:  2008-09-09       Impact factor: 31.743
  9 in total
  5 in total

1.  Separate calculation of DW-MRI in assessing therapeutic effect in liver tumors in rats.

Authors:  Feng Chen; Frederik De Keyzer; Yuan-Bo Feng; Marlein Miranda Cona; Jie Yu; Guy Marchal; Raymond Oyen; Yi-Cheng Ni
Journal:  World J Gastroenterol       Date:  2013-12-21       Impact factor: 5.742

2.  Non-small-cell lung cancer: molecular targeted therapy and personalized medicine - drug resistance, mechanisms, and strategies.

Authors:  Marybeth Sechler; Amber D Cizmic; Sreedevi Avasarala; Michelle Van Scoyk; Christine Brzezinski; Nicole Kelley; Rama Kamesh Bikkavilli; Robert A Winn
Journal:  Pharmgenomics Pers Med       Date:  2013-04-04

Review 3.  PI3K functions in cancer progression, anticancer immunity and immune evasion by tumors.

Authors:  Francesco Dituri; Antonio Mazzocca; Gianluigi Giannelli; Salvatore Antonaci
Journal:  Clin Dev Immunol       Date:  2011-10-20

4.  Enhanced antitumor efficacy of a vascular disrupting agent combined with an antiangiogenic in a rat liver tumor model evaluated by multiparametric MRI.

Authors:  Feng Chen; Yingmei Feng; Kaier Zheng; Frederik De Keyzer; Junjie Li; Yuanbo Feng; Marlein Miranda Cona; Huaijun Wang; Yansheng Jiang; Jie Yu; Guy Marchal; Catherine Verfaillie; Bart De Geest; Raymond Oyen; Yicheng Ni
Journal:  PLoS One       Date:  2012-07-18       Impact factor: 3.240

Review 5.  [A Literature Review on the Role of TBX5 in Expression and Progression of Lung Cancer: Current Perspectives].

Authors:  Weijia Huang; Peiwei Li; Xiaoming Qiu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2020-08-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.